
## Laurence D Sterns

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3878092/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Catheter ablation for persistent atrial fibrillation: A multicenter randomized trial of pulmonary vein isolation (PVI) versus PVI with posterior left atrial wall isolation (PWI) - The CAPLA study. American Heart Journal, 2022, 243, 210-220.	1.2	21
2	Comparative effectiveness of ventricular tachycardia ablation vs. escalated antiarrhythmic drug therapy by location of myocardial infarction: a sub-study of the VANISH trial. Europace, 2022, 24, 948-958.	0.7	1
3	Novel ventricular tachyarrhythmia detection enhancement detects undertreated life-threatening arrhythmias. Heart Rhythm O2, 2022, 3, 70-78.	0.6	6
4	Ventricular tachycardia characteristics and outcomes with catheter ablation vs. antiarrhythmic therapy: insights from the VANISH trial. Europace, 2022, 24, 1112-1118.	0.7	4
5	Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial. Circulation, 2022, 145, 1693-1704.	1.6	54
6	Canadian Registry of Electronic Device Outcomes (CREDO): The Abbott ICD Premature Battery Depletion Advisory, a Multicentre Cohort Study. CJC Open, 2021, 3, 48-53.	0.7	1
7	Remote-only monitoring for patients with cardiac implantable electronic devices: a before-and-after pilot study. CMAJ Open, 2021, 9, E53-E61.	1.1	7
8	Canadian Registry of Electronic Device Outcomes: remote monitoring outcomes in the Abbott battery performance alert—a multicentre cohort. Europace, 2021, 23, 1319-1323.	0.7	2
9	Canadian national electrophysiology ablation registry report 2011–2016. BMC Health Services Research, 2021, 21, 435.	0.9	3
10	2021 Update on Safety of Magnetic Resonance Imaging: Joint Statement From Canadian Cardiovascular Society/Canadian Society for Cardiovascular Magnetic Resonance/Canadian Heart Rhythm Society. Canadian Journal of Cardiology, 2021, 37, 835-847.	0.8	10
11	Additional antitachycardia pacing programming strategies further reduce unnecessary implantable cardioverter-defibrillator shocks. Heart Rhythm, 2020, 17, 98-105.	0.3	7
12	Efficacy and Safety of Same-Day Discharge for Atrial Fibrillation Ablation. JACC: Clinical Electrophysiology, 2020, 6, 609-619.	1.3	47
13	Mortality Risk Increases With Clustered Ventricular Arrhythmias in Patients With Implantable Cardioverter-Defibrillators. JACC: Clinical Electrophysiology, 2020, 6, 327-337.	1.3	15
14	SVT discrimination algorithms significantly reduce the rate of inappropriate therapy in the setting of modernâ€day delayed highâ€rate detection programming. Journal of Cardiovascular Electrophysiology, 2019, 30, 2877-2884.	0.8	5
15	Optimum lesion set and predictors of outcome in persistent atrial fibrillation ablation: a meta-regression analysis. Europace, 2019, 21, 1176-1184.	0.7	20
16	Mexiletine or catheter ablation after amiodarone failure in the VANISH trial. Journal of Cardiovascular Electrophysiology, 2018, 29, 603-608.	0.8	26
17	Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005663.	2.1	18
18	Cost Effectiveness of Ventricular Tachycardia Ablation Versus Escalation of Antiarrhythmic Drug Therapy. JACC: Clinical Electrophysiology, 2018, 4, 660-668.	1.3	27

LAURENCE D STERNS

#	Article	IF	CITATIONS
19	Canadian Registry of Implantable Electronic Device Outcomes: Longer-term follow-up of the Riata lead under advisory. Heart Rhythm, 2018, 15, 524-529.	0.3	4
20	Estimating the incidence of atrial fibrillation in singleâ€chamber implantable cardioverter defibrillator patients. PACE - Pacing and Clinical Electrophysiology, 2018, 42, 132-138.	0.5	7
21	Outcomes of paroxysmal atrial fibrillation ablation studies are affected more by study design and patient mix than ablation technique. Journal of Cardiovascular Electrophysiology, 2018, 29, 1471-1479.	0.8	7
22	Canadian Registry of Implantable Electronic Device Outcomes: Surveillance of High-Voltage Leads. Canadian Journal of Cardiology, 2018, 34, 808-811.	0.8	2
23	Management of Implantable Cardioverter Defibrillator Recipients: Care Beyond Guidelines. Canadian Journal of Cardiology, 2017, 33, 977-990.	0.8	8
24	Inappropriate shocks in single-chamber and subcutaneous implantable cardioverter-defibrillators: a systematic review and meta-analysis. Europace, 2017, 19, 1973-1980.	0.7	38
25	Cardiac Resynchronization Therapy Reduces Ventricular Arrhythmias in Primary but Not Secondary Prophylactic Implantable Cardioverter Defibrillator Patients. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	31
26	Atrioventricular Nodal Non Re-Entrant Tachycardia (AVNNT). Heart Lung and Circulation, 2017, 26, 524-525.	0.2	3
27	Canadian Cardiovascular Society/Canadian Heart Rhythm Society 2016 Implantable Cardioverter-Defibrillator Guidelines. Canadian Journal of Cardiology, 2017, 33, 174-188.	0.8	84
28	Extended detection time to reduce shocks is safe in secondary prevention patients: The secondary prevention substudy of PainFree SST. Heart Rhythm, 2016, 13, 1489-1496.	0.3	24
29	Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. New England Journal of Medicine, 2016, 375, 111-121.	13.9	616
30	Ejectable loop recorders?. Heart Rhythm, 2016, 13, 2105.	0.3	2
31	Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results. Heart Rhythm, 2015, 12, 926-936.	0.3	130
32	Feedback to providers improves evidence-based implantable cardioverter-defibrillator programming and reduces shocks. Heart Rhythm, 2015, 12, 545-553.	0.3	11
33	Incidence, Predictors, and Procedural Results of Upgrade to Resynchronization Therapy. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 152-158.	2.1	29
34	Esophageal perforation after radiofrequency ablation for atrial fibrillation. Asian Cardiovascular and Thoracic Annals, 2014, 22, 1116-1118.	0.2	2
35	A Wide Complex Tachycardia with Changing Atrial Activation Sequence. PACE - Pacing and Clinical Electrophysiology, 2013, 36, e23-e26.	0.5	2
36	Do patients at high risk of nonsudden cardiac death benefit from prophylactic ICD therapy?. Current Opinion in Cardiology, 2012, 27, 1-7.	0.8	4

LAURENCE D STERNS

#	Article	IF	CITATIONS
37	Safety, efficacy, and performance of new discrimination algorithms to reduce inappropriate and unnecessary shocks: the PainFree SST clinical study design. Europace, 2011, 13, 1484-1493.	0.7	33
38	Response to Letter Regarding Article, "Complications Associated With Revision of Sprint Fidelis Leads: Report From the Canadian Heart Rhythm Society Device Advisory Committee― Circulation, 2011, 123, .	1.6	0
39	Ablation of atrial fibrillation after the retirement age: considerations on safety and outcome. Journal of Interventional Cardiac Electrophysiology, 2010, 28, 193-197.	0.6	19
40	Complications Associated With Revision of Sprint Fidelis Leads. Circulation, 2010, 121, 2384-2387.	1.6	88
41	Double Transseptal Puncture for Catheter Ablation of Atrial Fibrillation: Safety of the Technique and Its Use in the Outpatient Setting. Cardiology Research and Practice, 2010, 2010, 1-5.	0.5	9
42	Transesophageal Echocardiography for the Prevention of Embolic Complications After Catheter Ablation for Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2009, 20, 1217-1222.	0.8	15
43	Outcome of advisory implantable cardioverter-defibrillator replacement: One-year follow-up. Heart Rhythm, 2008, 5, 1675-1681.	0.3	66
44	Outcome of the Fidelis implantable cardioverter-defibrillator lead advisory: A report from the Canadian Heart Rhythm Society Device Advisory Committee. Heart Rhythm, 2008, 5, 639-642.	0.3	79
45	Use of an Intracardiac Electrogram Eliminates the Need for a Surface ECG during Implantable Cardioverterâ€Đefibrillator Followâ€Up. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 1432-1437.	0.5	7
46	Effect of a Taser shot to the chest of a patient with an implantable defibrillator. Heart Rhythm, 2006, 3, 339-341.	0.3	47
47	P2-58. Heart Rhythm, 2006, 3, S157-S158.	0.3	1
48	P1-38. Heart Rhythm, 2006, 3, S119-S120.	0.3	0
49	A Comparison of Empiric to Physician-Tailored Programming of Implantable Cardioverter-Defibrillators. Journal of the American College of Cardiology, 2006, 48, 330-339.	1.2	225
50	Pulmonary vein isolation is always associated with Troponin elevation. Heart Rhythm, 2005, 2, S313.	0.3	0
51	A trial design for evaluation of empiric programming of implantable cardioverter defibrillators to improve patient management. Current Controlled Trials in Cardiovascular Medicine, 2004, 5, 12.	1.5	11
52	QT Dispersion in 120 Electrocardiographic Leads in Patients with Structural Heart Disease. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 20-31.	0.5	3
53	Cesium chloride induced ventricular arrhythmias in dogs: three-dimensional activation patterns and their relation to the cesium dose applied. Basic Research in Cardiology, 2000, 95, 152-162.	2.5	27
54	944-116 Focal Activation Patterns of Cesium Chloride Induced Torsades-de Pointes Tachycardias. Journal of the American College of Cardiology, 1995, 25, 170A.	1.2	2

#	Article	IF	CITATIONS
55	992–114 Atrial Recordings for the Differentiation of Ventricular and Supraventricular Tachyarrhythmias. Journal of the American College of Cardiology, 1995, 25, 317A.	1.2	3
56	Advances in follow-up techniques for implantable defibrillators. American Heart Journal, 1994, 127, 1081-1085.	1.2	4